The FDA rejected ITM Isotope Technologies Munich’s radiotherapeutic ITM-11 (177Lu-edotreotide) due to manufacturing problems, issuing a complete refusal to approve. The decision delays a potential competitor to Novartis’ approved Lutathera for gastroenteropancreatic neuroendocrine tumors (GEP-NETs), with ITM noting the agency did not cite data or safety concerns.